HeartSciences

HSCS · NASDAQ

$3.13+$0.06 (+1.95%)TodayMarket closed · Oct 20, 4:12 PM ET

Prev close $3.07

HSCS analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $10.20 (+225.9% upside)

Low: $8.08
Now: $3.13
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

HSCS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Mar 24, 2026	Maintains	Buy	$9.20 → $8.00	19%
Ascendiant Capital	Dec 22, 2025	Maintains	Buy	$9.00 → $9.20	19%

The case for and against

Updated Jun 9, 2026

Bull case

HeartSciences is poised for significant growth with its AI-powered ECG diagnostic solutions that have the potential to transform the healthcare industry by making ECGs a more valuable tool for detecting heart disease. The company's MyoVista cloud software platform and wavECG device, which are both in the final stages of FDA approval, offer a scalable revenue opportunity through installation fees, SaaS usage fees, and marketplace fees for AI-ECG algorithms. While dilution and execution challenges pose potential risks, the company's successful 510(k) submission for the MyoVista device and upcoming commercialization of MyoVista Insights demonstrate a strong potential for future success and we maintain our buy rating with a price target of $9.20.

Bear case

HeartSciences is decreasing its expenses and raising its EPS estimates for FY26 and FY27 due to lack of visibility on commercial revenues. Additionally, the company has begun phase 1 rollout of its MyoVista Insights cloud-platform and is aiming for FDA clearance in the first half of CY2026, which may contribute to potential future revenues. However, there is still a lack of clarity on the company's commercialization strategy and revenue potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.